Last reviewed · How we verify
Trivalent OPV 4 week interval
Trivalent OPV 4 week interval is a Live attenuated oral vaccine Biologic drug developed by International Centre for Diarrhoeal Disease Research, Bangladesh. It is currently FDA-approved for Poliomyelitis prevention (poliovirus types 1, 2, and 3).
Trivalent OPV provides immunization against three serotypes of poliovirus (types 1, 2, and 3) by inducing mucosal and systemic immune responses through oral administration of live attenuated virus.
The Trivalent OPV vaccine was studied in a trial involving healthy infants, with the vaccine administered at a 4-week interval. The trial, titled "Poliovirus Vaccine Trial in Bangladesh," aimed to assess the immunogenicity of the Trivalent OPV vaccine in this population.
At a glance
| Generic name | Trivalent OPV 4 week interval |
|---|---|
| Sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh |
| Drug class | Live attenuated oral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains three live attenuated poliovirus strains that replicate in the intestinal tract, stimulating both local intestinal immunity (IgA) and systemic immunity (IgG). This oral route of administration promotes mucosal tolerance and herd immunity, as vaccinated individuals shed attenuated virus that can immunize contacts. The 4-week interval dosing schedule allows for sequential immune priming and boosting across multiple doses.
Approved indications
- Poliomyelitis prevention (poliovirus types 1, 2, and 3)
Common side effects
- Vaccine-derived poliovirus (VDPV) shedding
- Mild gastrointestinal symptoms
- Vaccine-associated paralytic poliomyelitis (VAPP) in immunocompromised recipients
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trivalent OPV 4 week interval CI brief — competitive landscape report
- Trivalent OPV 4 week interval updates RSS · CI watch RSS
- International Centre for Diarrhoeal Disease Research, Bangladesh portfolio CI
Frequently asked questions about Trivalent OPV 4 week interval
What is Trivalent OPV 4 week interval?
How does Trivalent OPV 4 week interval work?
What is Trivalent OPV 4 week interval used for?
Who makes Trivalent OPV 4 week interval?
What drug class is Trivalent OPV 4 week interval in?
What development phase is Trivalent OPV 4 week interval in?
What are the side effects of Trivalent OPV 4 week interval?
Related
- Drug class: All Live attenuated oral vaccine drugs
- Manufacturer: International Centre for Diarrhoeal Disease Research, Bangladesh — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Poliomyelitis prevention (poliovirus types 1, 2, and 3)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing